CG Oncology (CG Oncology) Marketable Securities : $489.04 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. CG Oncology's Marketable Securities for the quarter that ended in Mar. 2024 was $489.04 Mil.

CG Oncology's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($55.34 Mil) and increased from Dec. 2022 ($55.34 Mil) to Dec. 2023 ($179.41 Mil).

CG Oncology Marketable Securities Historical Data

The historical data trend for CG Oncology's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Marketable Securities Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Marketable Securities

55.34

179.41

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial			55.34	-	193.48	179.41	489.04

CG Oncology Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

CG Oncology (NAS:CGON) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

CG Oncology Marketable Securities Related Terms

Thank you for viewing the detailed overview of CG Oncology's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024